Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Reviva (NASDAQ: RVPH) will present data on negative symptoms for brilaroxazine from the Phase 3 RECOVER program at CNS Summit 2025 in Boston.
The presentation covers results from the double‑blind RECOVER trial in acute exacerbation of schizophrenia and the long‑term open‑label extension in clinically stable patients over one year. Poster Number 32 is scheduled for Nov 3 and Nov 4, 2025, 5:00–7:00 PM ET. The conference runs Nov 2–5, 2025. Abstracts and additional details are available on the CNS Summit 2025 website.
Details
News Market Reaction – RVPH
On Oct 28, the day this news came out, RVPH closed 2.42% below the previous close.
Data tracked by StockTitan Argus for the Oct 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a poster presentation at the CNS Summit 2025, taking place November 2-5, in Boston, Massachusetts.
Details for the poster presentation can be found below:
Title: Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year
Poster Number: 32
Date and Time: Monday, November 3rd and Tuesday November 4th from 5:00- 7:00 PM ET
Abstracts and additional details can be found at the CNS Summit 2025 website.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.